Effects of orally administered bisphosphonates on bone loss in a disuse osteopenia model involving the rat.
OBJECTIVE
This study was carried out to evaluate the effectiveness of two newly synthesized bisphosphonates (BPs) [Alendronate (4-amino-1-hydroxybutylidene-1, 1-bisphosphonic acid (AHBuBP)) and Neridronate (6-amino-1-hydroxyhexylidene-1,1-bisphosphonic acid (AHHexBP)], administered orally, in reducing experimentally induced bone loss.


METHODS
Unilateral sciatic nerve section was performed on the Sprague-Dawley rat to induce osteopenia in one of the hind limbs. Histomorphometric measurements of the tibial trabecular bone and femur ash content determinations were effected to assess the degree of osteopenia. For comparison Chlodronate (dichloromethylene-1-bisphosphonic acid (Cl2MBP) was employed as the reference drug.


CONCLUSIONS
The results of this investigation show that both BPs were significantly active in reducing the osteopenic process in the involved limb and were more active than Chlodronate.
Mian
M
M
Gentili Institute, Research Division, Pisa, Italy.
Benetti
D
D
Aloisi
R
R
Rosini
S
S
Fantozzi
R
R
Savarino
L
L
Stea
S
S
Donati
M E
ME
Paganetto
G
G
Pizzoferrato
A
A
D000284:Administration, Oral; D019386:Alendronate / Q000008:administration & dosage*; D000818:Animals; D015519:Bone Density / Q000187:drug effects; D001851:Bone Diseases, Metabolic / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D001862:Bone Resorption / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D004164:Diphosphonates / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D016896:Treatment Outcome
D004164:Diphosphonates; C053389:6-amino-1-hydroxyhexane-1,1-diphosphonate; D019386:Alendronate